Elamipretide Reverses Heart and Muscle Aging Without Resetting the Biological Clock

Aging-related decline in cardiac and skeletal muscle function is a leading driver of disability and mortality in older adults, with sarcopenia affecting up to 45% of seniors and heart failure being the primary cause of death in the elderly. Despite growing interest in geroprotective drugs, most candidates either affect developmental pathways rather than aging-specific biology, or show stronger benefits in males than females. Elamipretide (ELAM) is a novel mitochondria-targeted tetrapeptide that concentrates up to 1000-fold in the inner mitochondrial membrane, stabilizes cardiolipin, reduces proton leak, and enhances ATP production across a broad range of disease models.

Researchers from Harvard Medical School and the University of Washington conducted an 8-week ELAM treatment study in young (5-month) and old (24-month) male and female C57BL/6J mice delivered via subcutaneous osmotic minipumps. Frailty index (31 items), in vivo hindlimb plantar flexor muscle force, and echocardiography (including diastolic function via tissue Doppler) were assessed before and after treatment. Post-treatment, cardiac and gastrocnemius tissues were collected for bulk mRNA sequencing and cardiac DNA methylation microarray, enabling assessment of both transcriptomic and epigenetic biological age using validated multi-tissue clocks.

Aging significantly worsened all functional measures: frailty scores rose, global longitudinal strain (GLS) and ejection fraction fell, diastolic function deteriorated, and skeletal muscle force declined—particularly in females. ELAM treatment partially reversed these deficits: aged mice showed significantly improved GLS, ejection fraction, and skeletal muscle fatigue resistance, and frailty accumulation was mitigated in treated old animals. Importantly, skeletal muscle force improvements were notably sex-dependent, with female mice showing greater benefit.

Despite these robust functional improvements, neither transcriptomic age (assessed by multi-tissue transcriptomic clocks) nor epigenetic age (assessed by DNA methylation clocks in cardiac tissue) showed statistically significant reductions in most ELAM-treated groups. No significant changes in individual gene expression or CpG methylation sites were detected after correction for multiple comparisons. However, gene set enrichment and pathway analyses revealed that ELAM-induced transcriptomic shifts significantly correlated with mammalian longevity signatures, including upregulation of fatty acid oxidation, mitochondrial translation, and oxidative phosphorylation pathways, and downregulation of inflammatory gene networks—all hallmarks of longevity-associated gene expression patterns.

These findings carry important implications for aging biology and drug development. First, they demonstrate that ELAM is an effective geroprotector that improves both cardiac and skeletal muscle healthspan in a sex-inclusive manner—a notable advantage over many ITP-tested compounds. Second, and more conceptually provocative, the data reveal a dissociation between functional tissue rejuvenation and detectable changes in molecular biological age. This suggests that some age-related functional declines may be correctable without broadly resetting the epigenetic or transcriptomic aging program—raising questions about what biological age clocks actually measure and what they predict in the context of targeted mitochondrial therapies.